Acumapimod (BCT197)
For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
Our partners have a mission-critical role to play – providing the resources, skills and perspective that is integral to the development of therapies.
"We seek to leverage the strong development and regulatory progress Mereo has already made to continue the development of navicixizumab and ultimately make this investigational therapy available to patients as quickly as possible.”
Laura E. Benjamin, Ph.D., Chief Executive Officer of OncXerna
LONDON, January 08, 2024 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its pipeline programs as well as an update on recent corporate developments.
NOVATO, Calif., VANCOUVER, British Columbia and LONDON, UK — Oct. 14, 2023 — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab (UX143) significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD). The data were presented in a late-breaker presentation at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR).
Mereo BioPharma and Ultragenyx Pharmaceutical Inc. today announced that additional data relevant to setrusumab will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR) being held September 9-12, 2022, in Austin, Texas.
Mereo BioPharma's partner for the development of Navicixizumab, OncXerna Therapeutics Inc. announced that Navicixizumab Phase 1b data has been published in the Journal of Clinical Oncology.
Mereo actively seeks partners with aligning strategic priorities and values to ensure that we can unlock the full potential of our pipeline for all stakeholders, particularly patients.
We currently have one clinical-stage program with partnering opportunities.
For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
Mereo acquired a portfolio in July 2015 including Setrusumab, Acumapimod and Leflutrozole.
Mereo in-licensed Alvelestat from AstraZeneca In October 2017.
In December 2020, Mereo entered a collaboration and license for the development and co-commercialization of Setrusumab.
Mereo out-licensed Navicixizumab to OncXerna in January 2020.